Amgen beats by $0.28, reports revs in-line; guides FY23 EPS in-line, revs above consensus (263.19)
- Reports Q3 (Sep) earnings of $4.96 per share, excluding non-recurring items, $0.28 better than the FactSet Consensus of $4.68; revenues rose 3.7% year/year to $6.9 bln vs the $6.92 bln FactSet Consensus.
- Product sales growth was driven by 11% volume growth, partially offset by 3% lower net selling price and 3% unfavorable changes to estimated sales deductions.
Volume growth of 11% included double-digit volume growth from BLINCYTO (blinatumomab), EVENITY (romosozumab-aqqg), Repatha (evolocumab) and Nplate (romiplostim). - Co issues guidance for FY23, sees EPS of $18.20-$18.80 vs. $18.36 FactSet Consensus; sees FY23 revs of $28.0-$28.4 bln vs. $27.57 bln FactSet Consensus.